Analysts Swing to Diverse Views for Teladoc, Inc. (TDOC), ZIOPHARM Oncology, Inc. (ZIOP)

Shares of Teladoc, Inc. (NYSE:TDOC) opened at $41.75, and ended 0% lower at $41.95. Nearly 1.68 million shares were traded by the close, higher than its average daily volume of 1.12 million shares.

Teladoc, Inc. (TDOC) Analyst Opinion

Teladoc, Inc. has a consensus outperform rating from 16 Wall Street analysts, and the number of shares currently sold short amount to at least 33.06% of shares outstanding. The stock spiked 13.23% last month and is up 20.37 this year. Wall Street is only getting more bullish on the stock, with 13 of analysts who cover TDOC having a buy-equivalent rating. Analysts have placed a $42.13 price target on Teladoc, Inc., suggesting a 0.43% gain from recent close. It’s currently trading about -0.42% below its 52-week high.

Teladoc, Inc. Earnings Surprise

Teladoc, Inc. (TDOC) failed to surprise the stock market in its last reported earnings when it earned -$0.76 a piece versus the consensus-estimated -$0.51. Its revenue totaled $76.16 million up 10.94% from the previous quarter.

Teladoc, Inc. (NYSE:TDOC) Intraday View

This stock (TDOC) is ahead of its 52-week low with 114.03%. Its last month’s stock price volatility remained 7.98% which for the week stands at 5.86%. The share price has moved forward from its 20 days moving average, trading at a distance of 14.71% and stays 17.7% away from its 50 days moving average. Over the last five days, shares have managed 8.82% gains and now is up 25.39% since hitting its 200-day moving average of $33.76. Teladoc, Inc. (TDOC) has made its way to a 12-month gain of 88.12%.

Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $4.13 a gain of $0.09, on the trading floor. The stock, after opening at $4.04, touched a high of $4.42 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. ZIOPHARM Oncology, Inc. has 1 buy ratings, 4 holds and 0 sells even after the stock tumbled -47.59% from its high of $7.88 to a $581.03 million market value through last close.

ZIOPHARM Oncology, Inc. (ZIOP) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2.5 to 2.5 during a month. Analysts set a 12-month price target of $7.25 a share. The target implies a 75.54% spike from where the shares are currently trading. Also, the current price highlights a discount of 130.02% to analysts’ high consensus price target.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Intraday Trading

The counter witnessed a trading volume of 2.72 million shares versus an average volume of 1.89 million shares during last trading session. Its last month’s stock price volatility remained 8.24% which for the week approaches 7.88%. The lowest price the stock reached in the last trading day was $4.01 and compares with the $3.33 52-week low. The stock recovered 24.02% since its low point and has performed -0.24% year-to-date.

Previous articleVaried Analyst Comments On B&G Foods, Inc. (BGS), Ascena Retail Group, Inc. (ASNA)
Next articleAnalysts Give These Stocks Mix Nod: MiMedx Group, Inc. (MDXG), Radius Health, Inc. (RDUS)